Who are biomodal's decision-makers?
biomodal's operating decisions sit with its executive leadership, while technical, security, clinical, operations, or finance buyers vary by product area.
- CEO
- Peter Fromen
- CTO/key exec
- Fiona Stewart
- Founded
- 2012
- Employees
- About 111 / 101-200 public profile range
- HQ
- Cambridge, United Kingdom
- Notable
- Private; valuation not disclosed
- Peter FromenChief Executive OfficerCEO listed on current team pageLeads commercialization and company strategy.
- Fiona StewartChief Financial OfficerExecutive teamFinance leader for private life-sciences scale-up.
- biomodal leadership teamExecutive leadershipCurrent team pageCompany lists a broader scientific, commercial, and operational leadership team.
Who leads biomodal?
biomodal's leadership is represented by the public executives and founders in the profile leadership block. The most reliable sources are company leadership pages, official filings, and primary funding announcements.
Who actually makes buying decisions at biomodal?
Buying decisions depend on the use case: executive leadership sets strategy, while product, engineering, security, finance, clinical, operations, or procurement leaders own functional evaluation. Early private companies tend to route more decisions through founders; mature or public companies use formal procurement.
How is biomodal organized as it scales?
The public footprint suggests organization around Life sciences tools product delivery, customer implementation, and core corporate functions. Sellers should match outreach to the business function that owns the pain rather than sending broad executive-only messages.
As of June 2026.Sources:biomodal leadershipbiomodal homepage
biomodal — frequently asked questions
